• SSY Group won China NMPA production and registration clearances for four drugs, including potassium chloride injection, sodium hyaluronate eye drops, metoclopramide tablets.
• Clearances were granted as passing China’s generic consistency evaluation, supporting expansion in ICU infusions and preservative-free ophthalmology products.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SSY Group Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260806-12274712), on August 06, 2026, and is solely responsible for the information contained therein.